In a recent transaction, Balaji Gandhi, the Chief Financial Officer of Phreesia, Inc. (NYSE:PHR), sold 3,504 shares of the company's common stock. The sale, which took place on March 25, 2024, was executed at a weighted average price of $23.2112 per share, totaling over $81,332.
According to the details provided, the shares were sold in multiple transactions with prices ranging from $23.14 to $23.28. It is noted that the sales were part of a mandatory sell-to-cover policy by the issuer to satisfy tax withholding obligations related to the settlement of restricted stock units.
Following the transaction, Gandhi's direct ownership in the company stands at 94,030 shares of common stock. The sale was made public through a Form 4 filing with the Securities and Exchange Commission, with the transactions being completed in accordance with the company's pre-established trading guidelines.
Investors and shareholders of Phreesia can request additional information regarding the specific prices of shares sold within the reported range, if needed. The company, based in Wilmington, Delaware, specializes in business services and operates within the healthcare technology sector, offering a patient intake management platform.
This recent transaction provides insight into the trading activity of Phreesia's executives and may be of interest to current and potential investors monitoring the stock's performance and insider trading patterns.
InvestingPro Insights
As Phreesia, Inc. (NYSE:PHR) continues to navigate the healthcare technology market, recent data from InvestingPro provides a snapshot of the company's financial health and market performance. As of the last twelve months of Q4 2024, Phreesia's market capitalization stands at $1.38 billion, a reflection of investor sentiment and the company's potential for growth.
Despite not anticipating profitability this year, as noted in one of the InvestingPro Tips, Phreesia has demonstrated a significant revenue growth of 26.84% over the same period. This indicates a robust expansion in the company's operations, which could be a positive signal for investors looking for growth potential in the healthcare technology sector. Additionally, a large price uptick of 32.77% over the last six months suggests a rising investor confidence in the company's future prospects.
However, it is worth noting that Phreesia operates with a moderate level of debt and has not been profitable over the last twelve months, which are important considerations for investors. Moreover, the company does not pay a dividend, highlighting a reinvestment strategy in its growth initiatives rather than immediate returns to shareholders.
For those looking to delve deeper into Phreesia's financial metrics and gain more insights, InvestingPro offers additional tips. By using the coupon code PRONEWS24, readers can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, which includes comprehensive analysis and tips for informed investment decisions.
Investors interested in Phreesia's stock performance and future earnings can also look forward to the next earnings date scheduled for May 30, 2024. With a fair value estimate of $30 by analysts and an InvestingPro fair value of $27.02, the company's stock price could present a potential opportunity for investors.
To explore more about Phreesia's financials and performance, visit InvestingPro for a detailed analysis and additional InvestingPro Tips to guide your investment strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.